Autoimmune Hepatitis After Liver Transplantation

Rodrigo Liberal; Maria Serena Longhi; Charlotte Grant; Giorgina Mieli-Vergani; Diego Vergani

doi:10.1016/j.cgh.2011.10.028

Autoimmune Hepatitis After Liver Transplantation

Rodrigo Liberal, Maria Serena Longhi, Charlotte Grant, Giorgina Mieli-Vergani, Diego Vergani

Research output: Contribution to journal › Literature review › peer-review

72 Citations (Scopus)

Abstract

Liver transplantation is an effective treatment for patients with end-stage acute and chronic autoimmune hepatitis. However, despite the good outcomes reported, disease recurrence is relatively common in the allograft. In addition, autoimmunity and autoimmune liver disease can arise de novo after transplantation for non-autoimmune liver disorders. Little is known about the mechanisms by which autoimmune diseases develop after liver transplantation, but genetic factors, molecular mimicry, impaired regulatory T-cell responses, and exposures to new alloantigens might be involved. Regardless of the pathogenic mechanisms, it is important to remain aware of the existence of recurrent and de novo autoimmune hepatitis after liver transplantation; these disorders are similar to classic autoimmune hepatitis and are therefore not treated with standard antirejection strategies.

Original language	English
Pages (from-to)	346 - 353
Number of pages	8
Journal	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume	10
Issue number	4
DOIs	https://doi.org/10.1016/j.cgh.2011.10.028
Publication status	Published - Apr 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2011.10.028

Cite this

@article{ff28aeba780f432ab5805efcd0c08752,

title = "Autoimmune Hepatitis After Liver Transplantation",

abstract = "Liver transplantation is an effective treatment for patients with end-stage acute and chronic autoimmune hepatitis. However, despite the good outcomes reported, disease recurrence is relatively common in the allograft. In addition, autoimmunity and autoimmune liver disease can arise de novo after transplantation for non-autoimmune liver disorders. Little is known about the mechanisms by which autoimmune diseases develop after liver transplantation, but genetic factors, molecular mimicry, impaired regulatory T-cell responses, and exposures to new alloantigens might be involved. Regardless of the pathogenic mechanisms, it is important to remain aware of the existence of recurrent and de novo autoimmune hepatitis after liver transplantation; these disorders are similar to classic autoimmune hepatitis and are therefore not treated with standard antirejection strategies.",

author = "Rodrigo Liberal and Longhi, {Maria Serena} and Charlotte Grant and Giorgina Mieli-Vergani and Diego Vergani",

year = "2012",

month = apr,

doi = "10.1016/j.cgh.2011.10.028",

language = "English",

volume = "10",

pages = "346 -- 353",

journal = "CLINICAL GASTROENTEROLOGY AND HEPATOLOGY",

publisher = "Dove Medical Press Ltd.",

number = "4",

}

TY - JOUR

T1 - Autoimmune Hepatitis After Liver Transplantation

AU - Liberal, Rodrigo

AU - Longhi, Maria Serena

AU - Grant, Charlotte

AU - Mieli-Vergani, Giorgina

AU - Vergani, Diego

PY - 2012/4

Y1 - 2012/4

N2 - Liver transplantation is an effective treatment for patients with end-stage acute and chronic autoimmune hepatitis. However, despite the good outcomes reported, disease recurrence is relatively common in the allograft. In addition, autoimmunity and autoimmune liver disease can arise de novo after transplantation for non-autoimmune liver disorders. Little is known about the mechanisms by which autoimmune diseases develop after liver transplantation, but genetic factors, molecular mimicry, impaired regulatory T-cell responses, and exposures to new alloantigens might be involved. Regardless of the pathogenic mechanisms, it is important to remain aware of the existence of recurrent and de novo autoimmune hepatitis after liver transplantation; these disorders are similar to classic autoimmune hepatitis and are therefore not treated with standard antirejection strategies.

AB - Liver transplantation is an effective treatment for patients with end-stage acute and chronic autoimmune hepatitis. However, despite the good outcomes reported, disease recurrence is relatively common in the allograft. In addition, autoimmunity and autoimmune liver disease can arise de novo after transplantation for non-autoimmune liver disorders. Little is known about the mechanisms by which autoimmune diseases develop after liver transplantation, but genetic factors, molecular mimicry, impaired regulatory T-cell responses, and exposures to new alloantigens might be involved. Regardless of the pathogenic mechanisms, it is important to remain aware of the existence of recurrent and de novo autoimmune hepatitis after liver transplantation; these disorders are similar to classic autoimmune hepatitis and are therefore not treated with standard antirejection strategies.

U2 - 10.1016/j.cgh.2011.10.028

DO - 10.1016/j.cgh.2011.10.028

M3 - Literature review

VL - 10

SP - 346

EP - 353

JO - CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

JF - CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

IS - 4

ER -

Autoimmune Hepatitis After Liver Transplantation

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this